An automatic chemiluminescence immunoassay for a novel biomarker NT-IGFBP-4: analytical performance and clinical relevance in heart failure
The new automatic NT-IGFBP-4 (CLIA) assay offers a highly specific, sensitive and precise method for quantifying IGFBP-4 fragments. Its validated performance and disease association findings would enhance its diagnostic and prognostic potential in CVD research, particularly in heart failure.
Authors
- Yu Wu (ORCID: https://orcid.org/0000-0001-8055-8327)
- Litao Zhang (ORCID: https://orcid.org/0000-0003-4918-611X)
- Zhenlu Zhang (ORCID: https://orcid.org/0000-0002-1999-6536)
- Shuzheng Cao
- Jing Wang (ORCID: https://orcid.org/0000-0001-5620-3411)
- Ling Li (ORCID: https://orcid.org/0009-0001-1643-0633)
- Hui Wang (ORCID: https://orcid.org/0000-0002-8549-3398)
- Yi Zhang (ORCID: https://orcid.org/0000-0001-7338-8825)
- Juan Yang (ORCID: https://orcid.org/0000-0002-0739-6998)
- Xin Shu
- Yisha Jing
Institutions
- Wuhan University (CN)
- Wuhan Asia Heart Hospital (CN)
- Mindray (China) (CN)
Publication Details
- Journal
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1515/cclm-2025-0378
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00